Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode

This study is not yet open for participant recruitment.
Verified December 2012 by McGill University Health Center
Sponsor:
Collaborator:
ResMed
Information provided by (Responsible Party):
Marta Kaminska, McGill University Health Center
ClinicalTrials.gov Identifier:
NCT01746381
First received: December 4, 2012
Last updated: December 10, 2012
Last verified: December 2012
  Purpose

Home non-invasive ventilation (NIV) is the standard-of-care as initial therapy for patients with ALS with worsening symptoms or deteriorating respiratory function, and has been recommended by the American Academy of Neurology (AAN) practice parameter for ALS.

This study will compare the current standard BiST mode of ventilation with the new iVAPS mode. The main study hypothesis is that the iVAPS mode, initiated in a single daytime trial, will result in a reduction of the number of respiratory therapist interventions and changes in ventilator settings as compared with the standard BiST mode. This will be assessed over a period of one year. In addition this study will test whether the iVAPS mode is superior to BiST mode with respect to: comfort and ease of use; improvement in nighttime and daytime symptoms of hypoventilation; compliance (hours used per day); physiologic parameters (daytime and overnight oxygen saturation and transcutaneous CO2 level).


Condition Intervention
Amyotrophic Lateral Sclerosis (ALS)
Device: Non-invasive home ventilation

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Initiation of Long-term Home Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode During a Daytime Trial

Resource links provided by NLM:


Further study details as provided by McGill University Health Center:

Primary Outcome Measures:
  • Difference in the number of respiratory therapist interventions required using IVAPS vs BIST mode of ventilation in patients with ALS. [ Time Frame: One year ] [ Designated as safety issue: No ]
    The investigators define interventions as any complaint from the patient related to the ventilator that warrants an unscheduled visit from the respiratory therapist or a change in ventilator settings.


Secondary Outcome Measures:
  • Feasibility of initiating long term home ventilation in ALS patients using the Stellar 150 iVAPS mode during a single daytime trial. [ Time Frame: 1 month ] [ Designated as safety issue: No ]
    This will be determined by compliance with use of nocturnal ventilation at 1 month, and good control of nocturnal oxygenation and sleep-disordered breathing at 1 week.

  • Difference in symptoms with IVAPS vs. BiST in ALS patients [ Time Frame: 1,6,12 months ] [ Designated as safety issue: No ]
    The investigators will use a questionnaire to assess hypoventilation-related symptoms and comfort with the ventilator.

  • Effectiveness of ventilation by IVAPS vs. BiST on night-time respiratory parameters in ALS patients [ Time Frame: 1 week, 6 months, 12 months ] [ Designated as safety issue: No ]
    This will be measured at 1 week using the Embletta portable monitor and transcutaneous capnography, and at 6 and 12 months using overnight oximetry and transcutaneous capnography.

  • Long-term compliance with the use of nocturnal ventilation on IVAPS vs. BiST in ALS patients [ Time Frame: 1,6,12 months ] [ Designated as safety issue: No ]
    This will be determined by the number of hours use per day recorded by the device.


Estimated Enrollment: 30
Study Start Date: February 2013
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IVAPS mode of non-invasive ventilation
Patients with ALS randomized to this arm will be treated with non-invasive home ventilation using the Intelligent Volume-Assured Pressure Support (IVAPS) mode
Device: Non-invasive home ventilation
A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
Other Name: Resmed Stellar 150
Active Comparator: BIST mode of non-invasive ventilation
Patients with ALS who are randomized to this arm will receive non-invasive home ventilation with the traditional bilevel non-invasive ventilation in spontaneous/timed (BIST) mode
Device: Non-invasive home ventilation
A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
Other Name: Resmed Stellar 150

Detailed Description:

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that is incurable, progressive, manifested by muscle weakness and wasting, and caused by degeneration of motor neurones. The limited data available suggest the incidence of ALS in Canada to be approximately 2 per 100,000 persons. The disease is characterized by progressive weakness of respiratory muscles, leading to respiratory insufficiency which is often the cause of death in patients with ALS.

Home non-invasive ventilation (NIV) is the standard-of-care as initial therapy for patients with ALS with worsening symptoms or deteriorating respiratory function, and has been recommended by the American Academy of Neurology (AAN) practice parameter for ALS. The symptomatic and survival benefits offered by NIV to patients with ALS make the optimization of ventilation a priority in terms of physiological variables but also symptoms to improve comfort, and consequently, compliance.

The Intelligent Volume-Assured Pressure Support (iVAPS) is a ventilator mode on the Stellar 150 ventilator (Resmed) that uses an algorithm to target alveolar ventilation. It has a learning mode to determine the initial optimal settings to commence ventilation, and is an adaptive mode, which constantly monitors the patient's spontaneous ventilation and adjusts the level of pressure support to maintain target alveolar ventilation.

The aim of the study is to determine the feasibility of long-term non-invasive home ventilation in ALS patients using the Stellar 150 IVAPS mode, initiated during a single daytime trial, and to assess the number of respiratory therapist interventions subsequently required as well as several patient-centered outcomes. The study will be conducted among patients with ALS referred to the National Program of Home Ventilatory Assistance (NPHVA) at the Montreal Chest Institute. The province-wide program provides home ventilation services to patients with a variety of neuromuscular and other disorders. Referred patients will be randomized to receive traditional Bilevel ventilation in ST mode (BiST) or iVAPS and will be followed over a period of one year. Respiratory therapist interventions (beyond scheduled visits) and changes in ventilator settings will be based on patient complaints and aimed at optimizing patient comfort and ventilator use. In addition, symptoms questionnaires will be administered regularly, home polygraphy (at 1 week), overnight oxymetry and transcutaneous capnography (at 6 and 12 months) will be performed. Compliance data will be assessed regularly from ventilator memory downloads at each of the scheduled respiratory therapist home visits (1 week, 1,6 and 12 months).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients referred to the National Program of Home Ventilatory Assistance (NPHVA) at the Montreal Chest Institute for home ventilation.
  • Patients that meet eligibility criteria for home ventilation as per the Quebec Health Ministry reference frame document for home ventilation (http://publications.msss.gouv.qc.ca/acrobat/f/documentation/2011/11-936-01W.pdf).
  • Adequate knowledge of English or French to complete study questionnaires.

Exclusion Criteria:

- The lack of eligibility for home ventilation, as per the document mentioned above

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01746381

Contacts
Contact: Marta Kaminska, MD,MSc 514-934-1934 ext 36117 marta.kaminska@mcgill.ca

Locations
Canada, Quebec
Montreal Chest Institute Not yet recruiting
Montreal, Quebec, Canada, H2W2E6
Contact: Marta Kaminska, MD,MSc         
Principal Investigator: Marta Kaminska, MD,MSc         
Sub-Investigator: Lancelot M Pinto, MD,MSc         
Sponsors and Collaborators
Marta Kaminska
ResMed
Investigators
Principal Investigator: Marta Kaminska, MD,MSc McGill University Health Center
Principal Investigator: Rita Troini, RRT,MSc McGill University Health Center
  More Information

Additional Information:
Publications:
Responsible Party: Marta Kaminska, Assistant professor, McGill University Health Center
ClinicalTrials.gov Identifier: NCT01746381     History of Changes
Other Study ID Numbers: 2902
Study First Received: December 4, 2012
Last Updated: December 10, 2012
Health Authority: Canada: Canadian Institutes of Health Research

Keywords provided by McGill University Health Center:
amyotrophic lateral sclerosis
non-invasive ventilation
home ventilation
IVAPS
neuromuscular diseases

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Sclerosis
Motor Neuron Disease
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
TDP-43 Proteinopathies
Neuromuscular Diseases
Proteostasis Deficiencies
Metabolic Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on April 17, 2014